Key facts
- It has raised $20.9M; the latest was Grant ($1.8M) in Aug 2025.
- Notable investors include Tech Incubator Program for Startup, Korea Investment Partners, Schmidt (South Korea), Shinhan Capital, Premier Partners — 19 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for Microbiotix
- ·The full record, as it builds
Funding rounds
No funding rounds for Microbiotix are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Microbiotix
Developer of therapeutic diagnostic technologies designed to facilitate the healthcare sector. The company's platform can utilize safe gastrointestinal microbiota transplant in a medical environment, formulate FMT capsules for oral administration, and research and develop bacteriophages, enabling patients to receive treatment conveniently and economically without infection.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2016
- Employees
- 41
- Website
- microbiotix.net/
- Ownership
- Privately Held (backing)
Microbiotix doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Microbiotix shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Microbiotix in its N-PORT filings yet. We sweep new filings monthly.